Key facts
- This page summarizes Samuel Bates Martin's Form 4 filing for Celldex Therapeutics, Inc. (CLDX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 06 Jan 2026, 16:23.
Samuel Bates Martin - 02 Jan 2026 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)
- Reporting relationship
- SVP AND CFO
- Issuer ticker
- CLDX
- Reported as of
- 02 Jan 2026
- Net transaction value
- +$50,000
- SEC form
- 4
- Accepted by SEC
- 06 Jan 2026, 16:23:48 UTC
- Prior SEC filing
- 09 Jun 2025
- Next SEC filing
- 29 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Anthony S. Marucci, attorney-in-fact for Samuel Bates Martin
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Samuel Bates Martin filed Form 4 for Celldex Therapeutics, Inc. (CLDX) on 06 Jan 2026.
Change
- Previous filing in this sequence was filed on 09 Jun 2025.
- Current net transaction value: +$50,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001709024
Primary reporting owner
Martin Samuel Bates
- Relationship
- SVP AND CFO
- Address
- C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON
- Signature
- /s/ Anthony S. Marucci, attorney-in-fact for Samuel Bates Martin
- Signature date
- 06 Jan 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CLDX
transaction
Common Stock
Options Exercise
- Transaction value
- $50,000
- Shares
- +4,817
- Change %
- +17%
- Price
- $10.38
- Shares after
- 32,942
- Date
- 02 Jan 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CLDX
transaction
Derivative
Incentive Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -4,817
- Change %
- -7.6%
- Price
- $0.000000
- Shares after
- 58,815
- Date
- 02 Jan 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,817
- Exercise price
- $10.38
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
As of June 18, 2024, the option is fully vested.